NDAORALCAPSULEPriority Review
Approved
Nov 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
COMETRIQ (cabozantinib) by Exelixis is and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of ret, met, vegfr-1, -2 and -3, kit, trkb, flt-3, axl, ros1, tyro3, mer, and tie-2. First approved in 2012.
Drug data last refreshed 12h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMETRIQ (cabozantinib) is an oral small-molecule tyrosine kinase inhibitor approved by the FDA in November 2012 that targets multiple receptor tyrosine kinases including RET, MET, VEGFR, KIT, and others involved in oncogenesis, metastasis, and tumor angiogenesis. It is used to treat patients with medullary thyroid cancer and other advanced malignancies where it inhibits both tumor growth and the tumor microenvironment. The drug represents a multi-targeted kinase approach to overcoming resistance mechanisms in cancer.
$0.003BPart D
Peak5.4 years to LOECOMETRIQ is at peak commercial maturity with modest Part D utilization, suggesting a stable but potentially contracting commercial team as the product approaches LOE.
Mechanism of Action
and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Started Aug 2026
30 enrolled
Neurofibromatosis 1Plexiform Neurofibroma
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Started Feb 2026
16 enrolled
Clear Cell Renal Cell Carcinoma
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Started Dec 2025
150 enrolled
Neuroendocrine Tumors
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Started Sep 2025
720 enrolled
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Started May 2025
50 enrolled
Kidney CancerRenal Cell Cancer
Worked on COMETRIQ at Exelixis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.